Co-Administration of Lacosamide and Levetiracetam
Yes, lacosamide and levetiracetam can be safely co-administered as adjunctive therapy for partial-onset seizures in adults. Both medications are FDA-approved for adjunctive treatment of focal (partial-onset) seizures and have complementary mechanisms of action without significant pharmacokinetic interactions 1.
Evidence Supporting Combined Use
FDA Approval and Indications
- Levetiracetam is FDA-approved as adjunctive therapy for partial-onset seizures in adults and children ≥4 years old 1.
- Lacosamide is similarly approved as adjunctive therapy for focal-onset seizures in adults, adolescents, and children ≥4 years 2.
- Both medications are explicitly designed to be added to existing antiseizure medication regimens 1.
Clinical Trial Evidence
- In pooled safety analyses of lacosamide trials, 10.1% of patients taking lacosamide with concomitant levetiracetam discontinued due to adverse events, compared to 3.9% on placebo with levetiracetam—demonstrating acceptable tolerability of the combination 3.
- The combination was studied in 278 patients receiving lacosamide plus levetiracetam versus 103 receiving placebo plus levetiracetam, providing substantial safety data for this specific drug pairing 3.
Comparative Efficacy Data
- A 2018 retrospective study directly compared lacosamide and levetiracetam as add-on treatments in 58 patients with partial-onset seizures and found no statistically significant difference in seizure control rates between the two agents (p=0.238), suggesting they work through complementary mechanisms without antagonism 4.
- A 2023 randomized controlled trial demonstrated equipotency between lacosamide and levetiracetam monotherapy in new-onset focal epilepsy, with 43.3% achieving seizure freedom in both arms, further supporting their compatibility 5.
Practical Dosing Considerations
Standard Adjunctive Dosing
- Levetiracetam: Start at 500 mg twice daily, increase by 1000 mg/day every 2 weeks to a maximum of 3000 mg/day 1.
- Lacosamide: Typical adjunctive doses range from 200-600 mg/day in divided doses, with most adverse events being dose-related and occurring during titration 3, 2.
When to Add the Second Agent
- When seizures persist despite therapeutic levetiracetam concentrations, add an adjunctive antiseizure medication such as lacosamide rather than increasing levetiracetam beyond 3000 mg/day 6.
- The American Academy of Neurology guidelines support all newer antiepileptic drugs, including both levetiracetam and lacosamide, as appropriate for adjunctive treatment of refractory partial seizures in adults 7.
Safety Profile of the Combination
Tolerability Advantages
- Both medications have favorable cardiovascular safety profiles: levetiracetam causes hypotension in only 0.7% of patients, while lacosamide's most common adverse events are dizziness (30.6%), nausea (11.4%), and diplopia (10.5%) 6, 3.
- Neither medication requires cardiac monitoring during administration, unlike phenytoin or fosphenytoin 6.
- Levetiracetam does not require therapeutic drug monitoring or routine laboratory surveillance due to linear pharmacokinetics and minimal drug interactions 8.
Common Pitfalls to Avoid
- Do not use fixed doses of levetiracetam instead of weight-based dosing in acute settings, as this leads to subtherapeutic levels in larger patients 9.
- Monitor for behavioral adverse effects with levetiracetam, particularly in patients with psychiatric history, as it can precipitate depression and mood disturbances 8.
- Titrate lacosamide slowly to minimize dose-related adverse events (dizziness, diplopia, nausea), which are most common during the titration phase 3.
Clinical Algorithm for Sequential Addition
- Start with levetiracetam monotherapy at 500 mg twice daily for newly diagnosed focal epilepsy 1.
- Titrate to 1000-1500 mg twice daily over 2-4 weeks based on response 1.
- If seizures persist at therapeutic doses (3000 mg/day total), add lacosamide as adjunctive therapy rather than exceeding maximum levetiracetam dosing 6.
- Initiate lacosamide at 100 mg/day and titrate by 100 mg/week to 200-400 mg/day to minimize adverse events 3, 2.
- Monitor for additive CNS effects (somnolence, dizziness) during the first 4-6 weeks of combination therapy 3.
Special Populations
Acute Seizure Management
- For benzodiazepine-refractory status epilepticus, levetiracetam 60 mg/kg IV (maximum 4500 mg) achieves seizure cessation in approximately 47% of patients—comparable to fosphenytoin and valproate 9, 6.
- Lacosamide has demonstrated efficacy as a second-line agent in critically ill children with acute repetitive seizures, with effectiveness rates of 100% when used as first choice and 85.7% as second choice 10.